Impact Biomedical INC 10-Q quarterly reports

Impact BioMedical reports a net loss of $2.28 million for Q1 2026, a significant increase from the prior year, primarily due to substantial stock-based compensation expenses.

Impact BioMedical reported a significant net loss for Q3 2025, driven by a fair value adjustment on related-party debt, while pursuing strategic acquisitions and a major merger.

Impact BioMedical, Inc. reported a significant increase in net loss for Q2 2025, driven by fair value adjustments on related-party debt and higher operating expenses, raising going concern doubts.

Impact BioMedical's Q1 2025 results reveal an increased net loss compared to Q1 2024, driven by higher operating expenses following its initial public offering.

Impact BioMedical reported a significant increase in net income for the third quarter of 2024, driven by cost-cutting measures and a favorable change in the fair value of embedded derivatives.

Impact BioMedical reported a net loss for the second quarter of 2024, while continuing to focus on its IPO and the monetization of its intellectual property.

Impact BioMedical's first quarter 2024 results show an increased net loss compared to the same period last year, primarily due to costs associated with its initial public offering.